A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder

Journal of Clinical Psychiatry

Volumn 69, Issue 3, 2008, Pages 412-417

  Bystritsky, Alexander ^a   Kerwin, Lauren ^a   Feusner, Jamie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; LORAZEPAM; NIRAVAM; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED STUDY; ELECTROSTIMULATION THERAPY; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL;

EID: 42249097909     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0311     Document Type: Article

References (61)

1. Regier DA, Rae DS, Narrow WE, et al. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry Suppl 1998;34:24-28
2. Kessler RC. The epidemiology of pure and comorbid generalized anxiety disorder: a review and evaluation of recent research. Acta Psychiatr Scand Suppl 2000;406:7-13
3. Rucci P, Gherardi S, Tansella M, et al. Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. J Affect Disord 2003;76:171-181
4. Brawman-Mintzer O, Lydiard RB. Biological basis of generalized anxiety disorder. J Clin Psychiatry 1997;58(suppl 3):16-25; discussion 26
5. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 2001;24:19-39
6. Kessler RC, Wittchen HU. Patterns and correlates of generalized anxiety disorder in community samples. J Clin Psychiatry 2002;63(suppl 8):4-10
7. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160:749-756
8. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002;63(suppl 14):9-16
9. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004;24:488-496
10. Laakmann G, Schule C, Lorkowski G, et al. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 1998;136:357-366
11. Electrosleep and cerebral electrotherapy. Med Lett Drugs Ther 1971;13:81-82
12. Flemenbaum A. Cerebral electrotherapy (electrosleep): an open-clinical study with a six month follow-up. Psychosomatics 1974;15:20-24
13. Kirsch DL, Smith RB. The use of cranial electrotherapy stimulation in the management of chronic pain: a review. NeuroRehabilitation 2000;14:85-94
14. Long RC. Electrosleep therapy: some results with the use of electrically induced sleep in the treatment of psychiatric patients. J Kans Med Soc 1966;67:81-85
15. Arian E. [Electrosleep; clinical experiences]. Minerva Med 1957;48:1828-1833
16. Buckman C, Pinsley I, Fenichel M. Electrosleep therapy in psychoses. Dis Nerv Syst 1957;18:106-108
17. Solomon S, Elkind A, Freitag F, et al. Safety and effectiveness of cranial electrotherapy in the treatment of tension headache. Headache 1989;29:445-450
18. Schmitt R, Capo T, Frazier H, et al. Cranial electrotherapy stimulation treatment of cognitive brain dysfunction in chemical dependence. J Clin Psychiatry 1984;45:60-63
19. Schmitt R, Capo T, Boyd E. Cranial electrotherapy stimulation as a treatment for anxiety in chemically dependent persons. Alcohol Clin Exp Res 1986;10:158-160
20. Jenkins JB, Spensley J. Electrosleep therapy. Nurs Times 1971;67:1310-1312
21. Flemenbaum A. Cerebral electrotherapy (electrosleep): a review. Curr Psychiatr Ther 1975;15:195-202
22. Moore JA, Mellor CS, Standage KF, et al. A double-blind study of electrosleep for anxiety and insomnia. Biol Psychiatry 1975;10:59-63
23. Krupitsky EM, Burakov AM, Karandashova GF, et al. The administration of transcranial electric treatment for affective disturbances therapy in alcoholic patients. Drug Alcohol Depend 1991;27:1-6
24. Philip P, Demotes-Mainard J, Bourgeois M, et al. Efficiency of transcranial electrostimulation on anxiety and insomnia symptoms during a washout period in depressed patients: a double-blind study. Biol Psychiatry 1991;29:451-456
25. Smith RB, Tiberi A, Marshall J. The use of cranial electrotherapy stimulation in the treatment of closed-head-injured patients. Brain Inj 1994;8:357-361
26. Klawansky S, Yeung A, Berkey C, et al. Meta-analysis of randomized controlled trials of cranial electrostimulation: efficacy in treating selected psychological and physiological conditions. J Nerv Ment Dis 1995;183:478-484
27. Jarzembski WB. Electrical stimulation and substance abuse treatment. Neurobehav Toxicol Teratol 1985;7:119-123
28. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
29. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
30. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33; quiz 34-57
31. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
32. Guy W. Patient assessment in clinical trials. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:601-606
33. Bystritsky A, Waikar SV, Vapnik T. Four-Dimensional Anxiety and Depression Scale: a preliminary psychometric report. Anxiety 1996;2:47-50
34. Bystritsky A, Wagner AW, Russo JE, et al. Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders. Gen Hosp Psychiatry 2005;27:313-318
35. Bystritsky A, Stoessel P, Yager J. Psychometric discrimination between anxiety and depression. J Nerv Ment Dis 1993;181:265-267
36. Bystritsky A, Shapiro D. Continuous physiological changes and subjective reports in panic patients: a preliminary methodological report. Biol Psychiatry 1992;32:766-777
37. Matson JL, Mayville EA, Bielecki J, et al. Reliability of the Matson Evaluation of Drug Side Effects Scale (MEDS). Res Dev Disabil 1998;19:501-506
38. Ferdjallah M, Bostick FX Jr, Barr RE. Potential and current density distributions of cranial electrotherapy stimulation (CES) in a fourconcentric-spheres model. IEEE Trans Biomed Eng 1996;43:939-943
39. Shealy CN, Cady RK, Wilkie RG, et al. Depression: a diagnostic, neurochemical profile and therapy with cranial electrotherapy stimulation (CES). J Neurol Orthop Med Surg 1989;10:319-321
40. Shealy CN, Cady RK, Wilkie RG, et al. Cerebral spinal fluid and plasma neurochemicals: response to cranial electrotherapy stimulation. J Neurol Orthop Med Surg 1998;18:94-97
41. Shealy CN. Transcutaneous electrical nerve stimulation: the treatment of choice for pain and depression. J Altern Complement Med 2003;9:619-623
42. Schroeder MJ, Barr RE. Quantitative analysis of the electroencephalogram during cranial electrotherapy stimulation. Clin Neurophysiol 2001;112:2075-2083
43. Boon P, Moors I, De Herdt V, et al. Vagus nerve stimulation and cognition. Seizure 2006;15:259-263
44. Paros A, Beck SL. Folinic acid reduces cleft lip [CL(P)] in A/WySn mice. Teratology 1999;60:344-347
45. Buchsbaum MS, Wu J, Haier R, et al. Positron emission tomography assessment of effects of benzodiazepines on regional glucose metabolic rate in patients with anxiety disorder. Life Sci 1987;40:2393-2400
46. Wu JC, Buchsbaum MS, Hershey TG, et al. PET in generalized anxiety disorder. Biol Psychiatry 1991;29:1181-1199
47. Hoehn-Saric R, McLeod DR, Funderburk F, et al. Somatic symptoms and physiologic responses in generalized anxiety disorder and panic disorder: an ambulatory monitor study. Arch Gen Psychiatry 2004;61:913-921
48. Carey PD, Warwick J, Niehaus DJ, et al. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 2004;4:30
49. Rickels K. Use of placebo in clinical trials. Psychopharmacol Bull 1986;22:19-24
50. Watson R. The placebo effect. J Clin Nurs 2006;15:519
51. Muhlack S, Lemmer W, Klotz P, et al. Anxiolytic effect of rescue remedy for psychiatric patients: a double-blind, placebo-controlled, randomized trial. J Clin Psychopharmacol 2006;26:541-542
52. Pollack MH. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 2001;62(suppl 19):20-25
53. Wager TD. Expectations and anxiety as mediators of placebo effects in pain. Pain 2005;115:225-226
54. Trexler LD, Karst TO. Rational-emotive therapy, placebo, and no-treatment effects on public-speaking anxiety. J Abnorm Psychol 1972;79:60-67
55. Segal MM, Shapiro KL. A clinical comparison study of the effects of reserpine and placebo on anxiety. AMA Arch Neurol Psychiatry 1959;81:392-398
56. Okada F. "Reverse placebo effects": anticipation/anxiety at the possibility of receiving placebos. Ann Pharmacother 1992;26:128
57. Mandos LA, Rickels K, Cutler N, et al. Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder. Int Clin Psychopharmacol 1995;10:251-256
58. Andreatini R, Sartori VA, Seabra ML, et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002;16:650-654
59. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexibledosage trial. J Clin Psychiatry 2001;62:350-357
60. Rickels K, Rynn M. Overview and clinical presentation of generalized anxiety disorder. Psychiatr Clin North Am 2001;24:1-17
61. Rickels K, Rynn MA. What is generalized anxiety disorder? J Clin Psychiatry 2001;62(suppl 11):4-12; discussion 13-14